CD8 (cluster of differentiation 8)

Our observation shows that high neutrophil levels in cancer patients are associated with poorer prognosis and increased risk of distant metastasis. Depletion of neutrophils reshapes the tumor immune microenvironment, wherein excessive inflammatory cytokines drive resistance to PD-1 antibody therapy.

The GEMs also improved the efficacy of ICIs in the ICI-resistant gene engineering tumor models and demonstrated significant anti-tumor efficacy in the metastasis models. Our study showed the potential clinical application of GEMs in the treatment of tumors.

FAM83D may be a key gene involved in the development and progression of HCC, contributing to early diagnosis and prognosis assessment. It has the potential to serve as a biomarker for HCC.

Furthermore, AR inhibitor finasteride and AR activator dihydrotestosterone (DHT) did not affect ZBTB7B...Notably, N-terminal domain (NTD) of AR is requisite for binding with ZBTB7B in HEK293 cells, not AR-DNA-binding domain (DBD) or AR-ligand-binding domain (LBD) in HEK293 cells. Overall, these findings provide a novel insight that ZBTB7B promotes prostate cancer progression as a potent oncogene via colocalization and binding with AR.

In primary human T cells, reduced CD2 costimulation impaired the magnitude of proliferation and IFN-γ production. These findings identify BAP1 as a central regulator of receptor expression and highlight CD2 as a tunable modulator of human T cell responses.

This rational engineering strategy addresses multiple barriers simultaneously through molecular sequestration, offering a promising platform applicable to alternative checkpoint-cytokine combinations and other cellular therapeutics. Clinical translation represents a critical next step for extending CAR-T efficacy to solid malignancies.

SIRT2 is upregulated in GC tissues and is associated with poor prognosis. It may serve as a promising biomarker for predicting GC progression and evaluating patient outcomes.

In low-resource settings, barriers such as limited access to advanced diagnostics and clinical trials necessitate tailored strategies to ensure equitable vaccine deployment. Overall, therapeutic cancer vaccines hold potential to become integrated into standard oncology protocols, especially for adjuvant therapy and recurrence prevention, with an emphasis on personalized and accessible immunotherapies to transform cancer management globally.

The random survival forest model demonstrated superior predictive performance, achieving a concordance index of 0.634 and time-dependent receiver operating characteristic area under the curve values of 0.973, 0.978, and 0.996 at 1, 2, and 3 years, respectively. In conclusion, this study identifies 12 critical drug resistance genes in PAAD and highlights the associated immune differences in patient risk, paving the way for targeted immunotherapy research to improve therapeutic strategies against this formidable disease.

This preliminary study demonstrates the feasibility of establishing an animal model for thymoma and myasthenia gravis (MG) pathogenesis research by transplanting human thymoma tissues into BALB/c nude mice. Nevertheless, several issues and challenges must be resolved and investigated in future research.

Immune infiltration analysis showed that RELT was significantly associated with immune cells such as B Cells, CD8+ T Cells, CD4+ T Cells, and Macrophages and may affect the tumor immune microenvironment of ccRCC by influencing macrophages. RELT promotes the development of ccRCC and may play a role in regulating the tumor immune microenvironment, which affects the prognosis of ccRCC patients, and RELT may become a new biomarker associated with immune infiltration in ccRCC.

These findings validate the broader utility of the previously identified HER2/neu-specific TCR repertoire and elucidate the molecular mechanisms driving its therapeutic efficacy, demonstrating the potential of TCR-T cells for treating solid tumors through robust cytotoxic activity and the emergence of a favorable CD4+CD8+ T cell population. This study offers critical mechanistic insights, establishing a foundation for advancing TCR-engineered therapies toward clinical use in HER2/neu-positive cancers.